Development of auto-IAP-antibody screening array for diagnosing cancer patients.

开发用于诊断癌症患者的自身 IAP 抗体筛查阵列。

• 批准号: 21390183
• 负责人: WATANABE Naoki
• 金额: $ 12.31万
• 依托单位: Sapporo Medical University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (B)
• 财政年份: 2009
• 资助国家: 日本
• 起止时间: 2009 至 2011
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21390183/
• 关键词: 腫瘍検査学; 腫瘍マーカー; IAPファミリー; Survivin; 自己抗体; 大腸癌; 大腸ポリープ; 腫瘍検査学; 腫瘍マーカー; IAPファミリー; Survivin; 自己抗体; 大腸癌; 大腸ポリープ

The inhibitor of-apoptosis(IAP) family proteins are shown to be advantageous to cancer in many circumstances, including carcinogenesis, promotion, and therapy resistance. In this study, we focused on expression of anti-survivin, anti-livin and anti-XIAP antibodies as tumor markers in patients with colorectal polyp and cancer, and developed the screening array that can be automated. We compared positivity of anti-survivin, anti-livin, and anti-XIAP antibodies with existing tumor markers, including carcinoembryonic antigen(CEA), carbohydrate antigen 19-9(CA19-9), and anti-p53 antibody. So far, positivity of anti-livin antibody in patients with colorectal cancer was low at 2. 4%; positivity of CEA, CA19-9, and anti-p53 antibody were 39. 8%, 21. 6%, and 25. 0%, respectively. Positivity of anti-survivin and anti-XIAP antibodies was higher than other tumor markers at 37. 5% and 36. 3%, respectively. Furthermore, expression of anti-survivin and anti-XIAP antibodies was found not only in patients with early stage colorectal cancer but also in patients with colorectal polyps.

在许多情况下，包括致癌，促进和耐药性在内，凋亡（IAP）家族蛋白的抑制剂被证明对癌症有利。在这项研究中，我们专注于表达结直肠息肉和癌症患者的抗溶毒素，抗LIVIN和抗XIAP抗体作为肿瘤标志物，并开发了可以自动化的筛查阵列。我们比较了抗溶毒素，抗livin和抗XIAP抗体与现有肿瘤标志物的阳性，包括癌胚抗原（CEA），碳水化合物抗原19-9（CA19-9）和抗p53抗体。到目前为止，结直肠癌患者的抗livin抗体的阳性在2。4％时较低。 CEA，CA19-9和抗P53抗体的阳性分别为39。8％，21。6％和25。0％。抗溶毒素和抗XIAP抗体的阳性分别高于其他肿瘤标志物，分别为37。5％和36。3％。此外，在早期结直肠癌的患者中，而且在结直肠息肉的患者中，抗塞维芬和抗XIAP抗体的表达不仅发现。